Clinical Trial: Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Renal Cell Cancer Metastatic
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2 Study of the Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue.
Brief Summary:
Fatigue is a prevalent adverse event associated with systemic therapy using tyrosine kinase inhibitors (TKIs).Meldonium, a fatty acid oxidation inhibitor, modifies the carnitine pathway, a nutrient critical for fat metabolism.The World Anti-Doping Agency (WADA) classified meldonium as a banned substance due to its documented use by athletes aiming to enhance physical performance.In this study, the safety and preliminary efficacy of meldonium in treatment-related fatigue will be assessed.
Read more